AR030937A1 - Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como agente antiinvasivo - Google Patents
Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como agente antiinvasivoInfo
- Publication number
- AR030937A1 AR030937A1 ARP010102704A ARP010102704A AR030937A1 AR 030937 A1 AR030937 A1 AR 030937A1 AR P010102704 A ARP010102704 A AR P010102704A AR P010102704 A ARP010102704 A AR P010102704A AR 030937 A1 AR030937 A1 AR 030937A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- group
- amino
- heterocyclyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Un derivado de quinazolina de formula (1), donde: m es 0, 1, 2 o 3; cada grupo R1, que puede ser el mismo o diferentes, se seleccionan entre halogeno, trifluorometilo, ciano, isociano, nitro, hidroxi, mercapto, amino, formilo, carboxi, carbamoílo, C1-6alquilo, C2-8alquenilo, C2-8alquinilo, C1-6alcoxi, C2-6alqueniloxi, C2-6alquiniloxi, C1-6alquiltio, C1-6alquilsulfinilo, C1-6alquilsulfonilo, C1-6alquilamino, di-(C1-6alquil)amino, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di(C1-6alquil)carbamoilo, C2-6alcanoilo, C2-6alcanoiloxi, C2-6alcanoilamino, N-C1-6alquil-C2-6alcanoilamino, C3-6alquenoilamino, N-C1-6alquil-C3-6alquenoilamino, C3-6alquiloilamino, N-C1-6alquil-C3-6alquiloilamino, N-C1-6alquilsulfamoilo, N,N-di-(C1-6alquil)sulfamoilo, C1-6alcanosulfonilamino y N-C1-6alquil-C1-6alcanosulfonilamino, o un grupo de formula: Q3-X1-, donde X1 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R4), CO, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, OC(R4)2, SC(R4)2 y N(R4)C(R4)2, donde R4 es hidrogeno o C1-6alquilo, y Q3 es arilo, aril-C1-6alquilo, C3-7cicloalquilo, C3-7cicloalquil-C1-6alquilo, C3-7cicloalquenilo, C3-7cicloalquenil-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo, o (R1)m es C1-3alquilendioxi, y donde los átomos de C adyacentes en cualquier cadena C2-6alquileno dentro de un sustituyente R1 se separan opcionalmente por la insercion en la cadena de un grupo seleccionada entre O, S, SO, SO2, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, CH=CH y CsC donde R5 es hidrogeno o C1-6alquilo, y donde cualquier CH2=CH- o HCsC- grupo dentro de un sustituyente R1 lleva opcionalmente en la posicion terminal CH2= o HCs un sustituyente seleccionado entre halogeno, carboxi, carbamoilo, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquil)carbamoilo, amino-C1-6alquilo, C1-6alquilamino-C1-6alquilo y di-(C1-6alquil)amino-C1-6alquilo o un grupo de formula: Q4-X2-, donde X2 es un enlace directo o se selecciona entre CO y N(R6)CO, donde R6 es hidrogeno o C1-6alquilo, y Q4 es arilo, aril-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo, y donde cualquier grupo CH2 o CH3 dentro de un sustituyente R1 lleva opcionalmente en cada caso uno de dichos grupos CH2 o CH3 uno o más sustituyentes halogeno o C1-6alquilo o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, C1-6alcoxi, C1-6alquiltio, C1-6alquilsulfinilo, C1-6alquilsulfonilo, C1-6alquilamino, di-(C1-6alquil)amino, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquil)carbamoilo, C2-6alcanoilo, C2-6alcanoiloxi, C2-6alcanoilamino, N-C1-6alquil-C2-6alcanoilamino, N-C1-6alquilsulfamoilo, N,N-di-(C1-6alquil)sulfamoilo, C1-6alcanosulfonilamino y N-C1-6alquil-C1-6alcanosulfonilamino, o un grupo de la formula: -X3-Q5 donde X3 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S y N(R7)C(R7)2, donde R7 es hidrogeno o C1-6alquilo, y Q5 es arilo, aril-C1-6alquilo, C3-7cicloalquilo, C3-7cicloalquil-C1-6alquilo, C3-7cicloalquenilo, C3-7cicloalquenil-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo, y donde cualquier grupo arilo, heteroarilo o heterociclilo dentro de un sustituyente en R1 lleva opcionalmente 1, 2 o 3 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halogeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, C1-6alquilo, C2-8alquenilo, C2-8alquinilo, C1-6alcoxi, C2-6alqueniloxi, C2-6alquiniloxi, C1-6alquiltio, C1-6alquilsulfinilo, C1-6alquilsulfonilo, C1-6alquilamino, di-(C1-6alquil)amino, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquil)carbamoilo, C2-6alcanoilo, C2-6alcanoiloxi, C2-6alcanoilamino, N-C1-6alquil-C2-6alcanoilamino, N-C1-6alquilsulfamoilo, N,N-di-(C1-6alquil)sulfamoilo, C1-6alcanosulfonilamino y N-C1-6alquil-C1-6alcanosulfonilamino, o un grupo de formula: -X4-R8 donde X4 es un enlace directo o se selecciona entre O y N(R9), donde R9 es hidrogeno o C1-6alquilo, y R8 es halogeno-C1-6alquilo, hidroxi-C1-6alquilo, C1-6alcoxi-C1-6alquilo, ciano-C1-6alquilo, amino-C1-6alquilo, C1-6alquilamino-C1-6alquilo, di-(C1-6alquil)amino-C1-6alquilo, C2-6alcanoilamino-C1-6alquilo o C1-6alcoxicarbonilamino-C1-6alquilo, o un grupo de formula: -X5-Q6 donde X5 es un enlace directo o se selecciona entre O, CO y N(R10), donde R10 es hidrogeno o C1-6alquilo, y Q6 es arilo, aril-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo que lleva opcionalmente 1 o 2 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halogeno, C1-6alquilo y C1-6alcoxi, y donde cualquier grupo heterociclilo dentro de un sustituyente en R1 lleva opcionalmente 1 o 2 sustituyentes oxo o tioxo; R2 es hidrogeno o C1-6alquilo; R3 es hidrogeno o C1-6alquilo; Z es un enlace directo o se selecciona entre O, S, SO, SO2, N(R11), CO, CH(OR11), CON(R11), N(R11)CO, SO2N(R11), N(R11)SO2, OC(R11)2, SC(R11)2 y N(R11)C(R11)2, donde R11 es hidrogeno o C1-6alquilo; Q1 es arilo, aril-C1-6alquilo, C3-7cicloalquilo, C3-7cicloalquil-C1-6alquilo, C3-7cicloalquenilo, C3-7cicloalquenil-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo, o cuando Z es un enlace directo u O, Q1 puede ser C1-6alquilo, C2-8alquenilo, C2-8alquinilo, halogeno-C1-6alquilo, hidroxi-C1-6alquilo, C1-6alcoxi-C1-6alquilo, ciano-C1-6alquilo, amino-C1-6alquilo, C1-6alquilamino-C1-6alquilo, di-(C1-6alquil)amino-C1-6alquilo, C1-6alquiltio-C1-6alquilo, C1-6alquilsulfinil-C1-6alquilo o C1-6alquilsulfonil-C1-6alquilo, y donde los átomos de C adyacentes en cualquier cadena C2-6alquileno dentro del grupo Q1-Z- se separan opcionalmente por la insercion en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R12), CO, CH(OR12), CON(R12), N(R12)CO, SO2N(R12), N(R12)SO2, CH=CH y CsC, donde R12 es hidrogeno o C1-6alquilo, y donde cualquier grupo CH2=CH- o HCsC dentro del grupo Q1-Z- lleva opcionalmente en la posicion terminal CH2= o HCs un sustituyente seleccionado entre halogeno, carboxi, carbamoilo, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquil)carbamoilo, amino-C1-6alquilo, C1-6alquilamino-C1-6alquilo y di(C1-6alquil)amino-C1-6alquilo o un grupo de formula: Q7-X6- donde X6 es un enlace directo o se selecciona entre CO y N(R13)CO, donde R13 es hidrogeno o C1-6alquilo, y Q7 es arilo, aril-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo, y donde cualquier grupo CH2 o CH3 dentro del grupo Q1-Z- lleva opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halogeno o C1-6alquilo o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, C1-6alcoxi, C1-6alquiltio, C1-6alquilsulfinilo, C1-6alquilsulfonilo, C1-6alquilamino, di-(C1-6alquilo)amino, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquilo)carbamoilo, C2-6alcanoilo, C2-6alcanoiloxi, C2-6alcanoilamino, N-C1-6alquil-C2-6alcanoilamino, N-C1-6alquilsulfamoilo, N,N-di-(C1-6alquil)sulfamoilo, C1-6alcanosulfamoilamino y N-C1-6alquil-C1-6alcanosulfamoilamino, o un grupo de formula X7-Q8 donde X7 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R14), CO, CH(OR14), CON(R14), N(R14)CO, SO2N(R14), N(R14)SO2, C(R14)2O, C(R14)2S y N(R14)C(R14)2, donde R14 es hidrogeno o C1-6alquilo, y Q8 es arilo, aril-C1-6alquilo, C3-7cicloalquilo, C3-7cicloalquil-C1-6alquilo, C3-7cicloalquenilo, C3-7cicloalquenil-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterociclil-C1-6alquilo, y donde cualquier grupo arilo, heteroarilo o heterociclilo dentro del grupo Q1-Z- lleva opcionalmente 1, 2 o 3 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halogeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, C1-6alquilo, C2-8alquenilo, C2-8alquinilo, C1-6alcoxi, C2-6alqueniloxi, C2-6alquiniloxi, C1-6alquiltio, C1-6alquilsulfinilo, C1-6alquilsulfonilo, C1-6alquilamino, di-(C1-6alquil)amino, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquil)carbamoilo, C2-6alcanoilo, C2-6alcanoiloxi, C2-6alcanoilamino, N-C1-6alquil-C2-6alcanoilamino, N-C1-6alquilsulfamoilo, N-di-(C1-6alquil)sulfamoilo, C1-6alcanosulfonilamino y N-C1-6alquil-C1-6alcanosulfonilamino, o un grupo de formula -X8-R15 donde X8 es un enlace directo o se selecciona entre O y N(R16), donde R16 es hidrogeno o C1-6alquilo, y R15 es halogeno-C1-6alquilo, hidroxi-C1-6alquilo, C1-6alcoxi-C1-6alquilo, ciano-C1-6alquilo, amino-C1-6alquilo, C1-6alquilamino-C1-6alquilo o di-(C1-6alquil)amino-C1-6alquilo, o un grupo de formula: X9-Q9 donde X9 es un enlace directo o se selecciona entre O, CO y N(R17) donde R17 es hidrogeno o C1-6alquilo, y Q9 es arilo, aril-C1-6alquilo, heteroarilo, heteroaril-C1-6alquilo, heterociclilo o heterocilil-C1-6alquilo que lleva opcionalmente 1 o 2 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halogeno, C1-6alquilo y C1-6alcoxi, y donde cualquier grupo heterociclilo dentro del grupo Q1-Z- lleva opcionalmente 1 o 2 sustituyentes oxo o tioxo; y Q2 es un grupo arilo de formula (2), donde: G1 se selecciona entre halogeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, C1-6alquilo, C2-8alquenilo, C2-8alquinilo, C1-6alcoxi, C2-6alqueniloxi, C2-6alquiniloxi, C1-6alquiltio, C1-6alquilsulfinilo, C1-6alquilsulfonilo, C1-6alquilamino, di-(C1-6alquil)amino, C1-6alcoxicarbonilo, N-C1-6alquilcarbamoilo, N,N-di-(C1-6alquil)carbamoilo, C2-6alcanoilo, C2-6alcanoiloxi, C2-6alcanoilamino, N-C1-6alquil-C2-6alcanoilamino, C3-6alquenoilamino, N-C1-6alquil-C3-6alquenoilamino, C3-6alquinoilamino, N-C1-6alquil-C3-6alquinoilamino, N-C1-6alquilsulfamoilo, N,N-di-(C1-6alquil)sulfamoilo, C1-6alcanosulfonilamino y N-C1-6alquil-C1-6alcanosulfonilamino, o un grupo de formula: -X10-R18 donde X10 es un enlace directo o se selecciona entre O y
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00401581 | 2000-06-06 | ||
EP01400297 | 2001-02-07 | ||
EP01400565 | 2001-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030937A1 true AR030937A1 (es) | 2003-09-03 |
Family
ID=27223613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010102704A AR030937A1 (es) | 2000-06-06 | 2001-06-06 | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como agente antiinvasivo |
Country Status (32)
Country | Link |
---|---|
US (3) | US7049438B2 (es) |
EP (1) | EP1292594B1 (es) |
JP (1) | JP3774438B2 (es) |
KR (2) | KR100807162B1 (es) |
CN (1) | CN100345844C (es) |
AR (1) | AR030937A1 (es) |
AT (1) | ATE275145T1 (es) |
AU (2) | AU2001260482B2 (es) |
BG (1) | BG65836B1 (es) |
BR (1) | BR0111335A (es) |
CA (1) | CA2407371C (es) |
CO (1) | CO5700751A2 (es) |
CZ (1) | CZ301987B6 (es) |
DE (1) | DE60105295T2 (es) |
DK (1) | DK1292594T3 (es) |
EE (1) | EE05481B1 (es) |
ES (1) | ES2225545T3 (es) |
HK (1) | HK1053115A1 (es) |
HU (1) | HU229290B1 (es) |
IL (2) | IL152754A0 (es) |
IS (1) | IS2114B (es) |
MX (1) | MXPA02011765A (es) |
MY (1) | MY127369A (es) |
NO (1) | NO324838B1 (es) |
NZ (1) | NZ522204A (es) |
PL (1) | PL210852B1 (es) |
PT (1) | PT1292594E (es) |
SI (1) | SI1292594T1 (es) |
SK (1) | SK286748B6 (es) |
TW (1) | TWI288748B (es) |
UA (1) | UA73993C2 (es) |
WO (1) | WO2001094341A1 (es) |
Families Citing this family (204)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0113358A (pt) | 2000-08-21 | 2003-07-01 | Astrazeneca Ab | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável |
WO2002030924A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
US6939866B2 (en) | 2000-10-13 | 2005-09-06 | Astrazeneca Ab | Quinazoline derivatives |
ATE502928T1 (de) | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
MXPA03008658A (es) * | 2001-03-23 | 2005-04-11 | Bayer Ag | Inhibidores de rho-cinasa. |
AR035792A1 (es) * | 2001-03-23 | 2004-07-14 | Bayer Corp | Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo |
EP1381599B1 (en) | 2001-04-19 | 2008-09-24 | Astrazeneca AB | Quinazoline derivatives |
ATE341545T1 (de) | 2001-07-16 | 2006-10-15 | Astrazeneca Ab | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
BR0213842A (pt) * | 2001-11-03 | 2004-08-31 | Astrazeneca Ab | Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável |
GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
WO2003047582A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
KR101093345B1 (ko) * | 2002-02-01 | 2011-12-14 | 아스트라제네카 아베 | 퀴나졸린 화합물 |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
EP1528925B1 (en) | 2002-07-09 | 2009-04-22 | Astrazeneca AB | Quinazoline derivatives for use in the treatment of cancer |
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
WO2004041829A1 (en) | 2002-11-04 | 2004-05-21 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
WO2004056801A1 (en) * | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | Quinazoline derivatives |
WO2004056812A1 (en) * | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
SI1667991T1 (sl) * | 2003-09-16 | 2008-10-31 | Astrazeneca Ab | Kinazolinski derivati kot inhibitorji tirozin kinaze |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
ATE517091T1 (de) | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
CN1914182B (zh) | 2004-02-03 | 2011-09-07 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
JP4205757B2 (ja) | 2004-05-06 | 2009-01-07 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 4−フェニルアミノ−キナゾリン−6−イル−アミド |
GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
UY29198A1 (es) * | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
CN101124228B (zh) * | 2004-12-14 | 2011-06-15 | 阿斯利康(瑞典)有限公司 | 用作抗肿瘤药物的吡唑并嘧啶化合物 |
GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2006081741A1 (fr) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances |
CN1854130B (zh) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
WO2007063293A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
EP1957499A1 (en) | 2005-12-02 | 2008-08-20 | AstraZeneca AB | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CN101583365B (zh) | 2006-12-15 | 2012-09-26 | 阿布拉西斯生物科学公司 | 三嗪衍生物及其治疗应用 |
WO2008077064A2 (en) * | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Biomarker identifying the reactivation of stat3 after src inhibition |
AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
NZ585261A (en) | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
WO2009057139A2 (en) | 2007-10-29 | 2009-05-07 | Natco Pharma Limited | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
EP2245026B1 (de) | 2008-02-07 | 2012-08-01 | Boehringer Ingelheim International GmbH | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
US9256904B1 (en) | 2008-08-14 | 2016-02-09 | Experian Information Solutions, Inc. | Multi-bureau credit file freeze and unfreeze |
US20100069340A1 (en) * | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
KR20110057244A (ko) | 2008-09-19 | 2011-05-31 | 메디뮨 엘엘씨 | Dll4에 대한 항체 및 이의 용도 |
CN101723906B (zh) * | 2008-10-10 | 2011-09-28 | 山西仁源堂药业有限公司 | 一种化合物、含该化合物的药物组合物及制备方法和用途 |
UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
WO2010072740A2 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
KR20110113755A (ko) | 2009-02-10 | 2011-10-18 | 아스트라제네카 아베 | 트리아졸로 〔4,3-b〕 피리다진 유도체 및 전립샘암에 대한 이의 용도 |
GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
EP2440053A4 (en) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
JP5785940B2 (ja) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス, エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
AR079050A1 (es) | 2009-11-18 | 2011-12-21 | Astrazeneca Ab | Compuestos benzoimidazolicos y sus usos |
HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
JP2013512859A (ja) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
CN103980338B (zh) | 2010-01-15 | 2017-04-26 | 苏州润新生物科技有限公司 | 蟾蜍灵衍生物、其药物组合物及用途 |
CA2786520A1 (en) | 2010-01-19 | 2011-07-28 | Astrazeneca Ab | Pyrazine derivatives |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
US9018197B2 (en) | 2010-08-28 | 2015-04-28 | Suzhou Neupharma Co. Ltd. | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use |
GB201016442D0 (en) | 2010-09-30 | 2010-11-17 | Pharminox Ltd | Novel acridine derivatives |
WO2012067268A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
KR20130105675A (ko) | 2010-11-25 | 2013-09-25 | 라티오팜 게엠베하 | 아파티닙의 신규 염 및 다형 |
EP3453714B1 (en) | 2011-02-02 | 2020-11-04 | Suzhou Neupharma Co., Ltd | Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof |
US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited | 選択的fak阻害剤 |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
US8530470B2 (en) | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
ME02382B (me) | 2011-07-27 | 2016-06-20 | Astrazeneca Ab | 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka |
US9295671B2 (en) | 2011-08-26 | 2016-03-29 | Neupharma, Inc. | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer |
AU2012308238B2 (en) | 2011-09-14 | 2017-05-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2013043935A1 (en) | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
US20140235573A1 (en) | 2011-09-29 | 2014-08-21 | The University Of Liverpool | Prevention and/or treatment of cancer and/or cancer metastasis |
US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
WO2013165924A1 (en) | 2012-04-29 | 2013-11-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
GB201211021D0 (en) | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
EP2885291A4 (en) | 2012-08-17 | 2015-11-04 | Cancer Therapeutics Crc Pty Ltd | INHIBITORS OF VEGFR3 |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
PL3381917T3 (pl) | 2013-01-31 | 2021-12-27 | Bellus Health Cough Inc. | Związki imidazopirydynowe i i ch zastosowania |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
WO2014144227A1 (en) | 2013-03-15 | 2014-09-18 | Magceutics, Inc. | Magnesium compositions and uses thereof for cancers |
WO2014195507A1 (en) | 2013-06-07 | 2014-12-11 | Universite Catholique De Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
CA2921410C (en) | 2013-08-23 | 2023-03-28 | Neupharma, Inc. | Quinazoline derivatives, compositions and their use as kinase inhibitors |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
EP3194572B1 (en) | 2014-07-30 | 2023-10-25 | Yeda Research and Development Co. Ltd. | Media for culturing pluripotent stem cells |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
WO2016130897A1 (en) | 2015-02-13 | 2016-08-18 | Yu Paul B | Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2017020065A1 (en) | 2015-08-04 | 2017-02-09 | University Of South Australia | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
CN109073650A (zh) | 2016-02-15 | 2018-12-21 | 阿斯利康(瑞典)有限公司 | 包括对西地尼布进行固定的间歇给药的方法 |
RS63609B1 (sr) | 2016-04-15 | 2022-10-31 | Cancer Research Tech Ltd | Heterociklična jedinjenja kao inhibitori ret kinaze |
GB2554333A (en) | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
KR101706346B1 (ko) | 2016-06-09 | 2017-03-13 | 서동균 | 건축물의 외벽 마감재 고정장치 |
JP7101165B2 (ja) | 2016-08-15 | 2022-07-14 | ニューファーマ, インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
ES2845048T3 (es) | 2016-09-22 | 2021-07-23 | Cancer Research Tech Ltd | Preparación y usos de derivados de pirimidinona |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
ES2906439T3 (es) | 2016-12-05 | 2022-04-18 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos |
SG11201907095UA (en) | 2017-02-01 | 2019-08-27 | Aucentra Therapeutics Pty Ltd | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS |
GB201704325D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
WO2018215798A1 (en) | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
EP3648797A1 (en) | 2017-07-05 | 2020-05-13 | EPOS-Iasis Research and Development, Ltd | Multifunctional conjugates |
US11447505B1 (en) | 2017-08-18 | 2022-09-20 | Cancer Research Technology Limited | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
CN107987064A (zh) * | 2017-12-30 | 2018-05-04 | 王兆举 | 一种治疗骨癌的药物塞卡替尼的制备方法 |
CN107814793A (zh) * | 2017-12-30 | 2018-03-20 | 胡张艳 | 一种小分子Src酪氨酸激酶抑制剂塞卡替尼及其中间体的制备方法 |
CN111757881A (zh) | 2018-01-15 | 2020-10-09 | 澳升控股有限公司 | 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物 |
GB201801128D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
KR20200143361A (ko) | 2018-02-08 | 2020-12-23 | 뉴파마, 인크. | 특정 화학 물질, 조성물, 및 방법 |
WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
EP3778589B1 (en) * | 2018-04-09 | 2022-05-11 | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier |
CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚(上海)生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
DK3774817T3 (da) | 2018-04-13 | 2023-02-13 | Cancer Research Tech Ltd | Bcl6-hæmmere |
GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
WO2019236496A1 (en) | 2018-06-04 | 2019-12-12 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
WO2020174420A1 (en) | 2019-02-27 | 2020-09-03 | Astrazeneca Ab | Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor |
EP3946618A1 (en) | 2019-04-05 | 2022-02-09 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
GB201908885D0 (en) | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
AU2020335054A1 (en) | 2019-08-31 | 2022-03-24 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivative for FGFR inhibitor and preparation method therefor |
EP4031249A1 (en) | 2019-09-20 | 2022-07-27 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
IL293340A (en) | 2019-12-02 | 2022-07-01 | Storm Therapeutics Ltd | Polyheterocyclic compounds as mettl3 inhibitors |
GB202004960D0 (en) | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
US20230183197A1 (en) | 2020-06-01 | 2023-06-15 | Neophore Limited | Inhibitors of mlh1 and/or pms2 for cancer treatment |
GB202012482D0 (en) | 2020-08-11 | 2020-09-23 | Univ Of Huddersfield | Novel compounds and therapeutic uses thereof |
GB202012969D0 (en) | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
WO2022074379A1 (en) | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
WO2022074391A1 (en) | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
CA3220146A1 (en) | 2021-05-17 | 2022-11-24 | Hk Inno.N Corporation | Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing of treating cancer containing the same as an active ingredient |
GB202107907D0 (en) | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
GB202110373D0 (en) | 2021-07-19 | 2021-09-01 | Neophore Ltd | Inhibitor compounds |
WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
GB202117225D0 (en) | 2021-11-29 | 2022-01-12 | Neophore Ltd | Protac compounds |
GB202117224D0 (en) | 2021-11-29 | 2022-01-12 | Neophore Ltd | Inhibitor compounds |
GB202202006D0 (en) | 2022-02-15 | 2022-03-30 | Chancellor Masters And Scholars Of The Univ Of Oxford | Anti-cancer treatment |
GB202202199D0 (en) | 2022-02-18 | 2022-04-06 | Cancer Research Tech Ltd | Compounds |
WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
GB202204935D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | Nanoparticles |
WO2023218201A1 (en) | 2022-05-11 | 2023-11-16 | Cancer Research Technology Limited | Ikk inhibitors |
GB202209404D0 (en) | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
WO2024030825A1 (en) | 2022-08-01 | 2024-02-08 | Neupharma, Inc | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
CZ288955B6 (cs) | 1994-02-23 | 2001-10-17 | Pfizer Inc. | Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (es) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
WO1999055683A1 (en) * | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
EP1082311A1 (en) * | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Quinazolines for treating brain tumor |
EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
HUP0103386A3 (en) | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
ATE232205T1 (de) | 1998-10-01 | 2003-02-15 | Astrazeneca Ab | Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird |
ES2241324T3 (es) | 1998-10-08 | 2005-10-16 | Astrazeneca Ab | Derivados de quinazolina. |
BR9915487A (pt) * | 1998-11-19 | 2001-07-31 | Warner Lambert Co | N-[4-(3-cloro-4-flúor-fenilamino) - 7 - (3-morfolin-4-il-propóxi)-quinazolin-6-il]-acrilamida, um inibidor irreversìvel de tirosina quinases |
DK1154774T3 (da) | 1999-02-10 | 2005-09-26 | Astrazeneca Ab | Quinazolinderivater som angiogenesisinhibitorer |
ID29800A (id) | 1999-02-27 | 2001-10-11 | Boehringer Ingelheim Pharma | Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6411963B1 (en) * | 1999-07-09 | 2002-06-25 | Junot Systems, Inc. | External system interface method and system |
CN1391561A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物和含有喹唑啉化合物的药物组合物 |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
CN1391562A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
SI1274692T1 (sl) | 2000-04-07 | 2006-12-31 | Astrazeneca Ab | Kinazolinske spojine |
BR0113358A (pt) | 2000-08-21 | 2003-07-01 | Astrazeneca Ab | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável |
-
2001
- 2001-01-06 UA UA2003010151A patent/UA73993C2/uk unknown
- 2001-06-01 HU HU0301046A patent/HU229290B1/hu not_active IP Right Cessation
- 2001-06-01 PL PL360745A patent/PL210852B1/pl unknown
- 2001-06-01 KR KR1020027016508A patent/KR100807162B1/ko not_active IP Right Cessation
- 2001-06-01 DK DK01934176T patent/DK1292594T3/da active
- 2001-06-01 CA CA002407371A patent/CA2407371C/en not_active Expired - Fee Related
- 2001-06-01 PT PT01934176T patent/PT1292594E/pt unknown
- 2001-06-01 NZ NZ522204A patent/NZ522204A/en not_active IP Right Cessation
- 2001-06-01 EP EP01934176A patent/EP1292594B1/en not_active Expired - Lifetime
- 2001-06-01 EE EEP200200673A patent/EE05481B1/xx not_active IP Right Cessation
- 2001-06-01 AU AU2001260482A patent/AU2001260482B2/en not_active Ceased
- 2001-06-01 AU AU6048201A patent/AU6048201A/xx active Pending
- 2001-06-01 CN CNB01810830XA patent/CN100345844C/zh not_active Expired - Lifetime
- 2001-06-01 JP JP2002501890A patent/JP3774438B2/ja not_active Expired - Lifetime
- 2001-06-01 IL IL15275401A patent/IL152754A0/xx unknown
- 2001-06-01 KR KR1020087002129A patent/KR20080015055A/ko not_active Application Discontinuation
- 2001-06-01 ES ES01934176T patent/ES2225545T3/es not_active Expired - Lifetime
- 2001-06-01 SK SK1702-2002A patent/SK286748B6/sk not_active IP Right Cessation
- 2001-06-01 US US10/275,382 patent/US7049438B2/en not_active Expired - Lifetime
- 2001-06-01 CZ CZ20023961A patent/CZ301987B6/cs not_active IP Right Cessation
- 2001-06-01 MX MXPA02011765A patent/MXPA02011765A/es active IP Right Grant
- 2001-06-01 DE DE60105295T patent/DE60105295T2/de not_active Expired - Lifetime
- 2001-06-01 SI SI200130193T patent/SI1292594T1/xx unknown
- 2001-06-01 BR BR0111335-6A patent/BR0111335A/pt not_active IP Right Cessation
- 2001-06-01 AT AT01934176T patent/ATE275145T1/de active
- 2001-06-01 WO PCT/GB2001/002424 patent/WO2001094341A1/en active IP Right Grant
- 2001-06-05 MY MYPI20012632 patent/MY127369A/en unknown
- 2001-06-06 AR ARP010102704A patent/AR030937A1/es active IP Right Grant
- 2001-06-06 TW TW090113714A patent/TWI288748B/zh not_active IP Right Cessation
-
2002
- 2002-11-11 IL IL152754A patent/IL152754A/en not_active IP Right Cessation
- 2002-11-28 BG BG107332A patent/BG65836B1/bg unknown
- 2002-12-02 NO NO20025792A patent/NO324838B1/no not_active IP Right Cessation
- 2002-12-02 IS IS6647A patent/IS2114B/is unknown
- 2002-12-30 CO CO02117241A patent/CO5700751A2/es active IP Right Grant
-
2003
- 2003-07-25 HK HK03105395A patent/HK1053115A1/xx not_active IP Right Cessation
-
2005
- 2005-11-21 US US11/283,415 patent/US7696214B2/en not_active Expired - Lifetime
-
2010
- 2010-01-29 US US12/696,489 patent/US20100280042A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030937A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como agente antiinvasivo | |
CO5540344A2 (es) | Medicamentos | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
SV2008001369A (es) | Benzimidazoles | |
PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
PE20021089A1 (es) | Compuestos de triazol como inhibidores de las citoquinas | |
AR064345A1 (es) | Derivados de 8-oxoadenina | |
CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
AR040336A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto | |
AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
AR057986A1 (es) | Compuesto heterociclico y su uso farmaceutico | |
PE20070108A1 (es) | Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida | |
AR035523A1 (es) | Uso de compuestos de aminoacetonitrilo para combatir animales daninos endoparasitarios en animales utiles y domesticos de sangre caliente | |
FI832644A (fi) | Amidderivat | |
CU23293B7 (es) | Derivados de 2-oxo-1-pirrolidina para prepararlos y sus usos | |
CO5680407A2 (es) | Inhibidores novedosos de cinasas | |
AR056199A1 (es) | Derivados de 8-oxoadenina 9-sustituida | |
ES2191183T3 (es) | Derivados 6,6- o 6,7-biciclicos que contienen pirido o pirimido sustituidos. | |
AR048042A1 (es) | Inhibidores no nucleosidos de transcriptasa inversa y composiciones farmaceuticas | |
AR057705A1 (es) | 3-acilaminobenzanilidas insecticidas | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
ES2180938T3 (es) | Donadores de oxido nitrico capaces de reducir la toxicidad de los farmacos. | |
TW200738620A (en) | Fluoroalkenyl derivatives as insecticides and nematicides | |
ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |